https://orcid.org/0000-0002-3853-5196
References
- Mohyuddin GR, Ouchveridize E, Goodman A, et al. The landscape of trials for smoldering multiple myeloma: end points, trial design and less than is learned. Leuk Lymphoma. 2021.
- Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma. 2013;54(10):2215–2218.
- Hill E, Dew A, Kazandjian D. State of the science in smoldering myeloma: Should we be treating in the clinic? Semin Oncol. 2019;46(2):112–120.
- Mateos M-V, Hernandez M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–447.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48–e548.
- Chang SH, Gumbel J, Luo S, et al. Post-MGUS diagnosis serum monoclonal-protein velocity and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2019;28(12):2055–2061.
- Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126–1137.
- Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020;34(7):1840–1852.
- Richard S, Jagannath S, Boccadoro M, et al. Should high-risk smouldering multiple myeloma be treated? The Lancet Haematology. 2020;7(1):e15–e6.
- Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol. 2020;95(6):672–690.